Dr Giulio Rosati receives poster prize at the General Assembly meeting of MICROB-PREDICT

by Virginia Greco

MICROB-PREDICT is an EU funded project aimed at developing new prevention and treatment tools for chronic liver disease (cirrhosis).

On 17-19 January 2023, the 5th General Assembly Meeting of the EU funded MICROB-PREDICT project was held in Budapest (Hungary). At the event, Dr Giulio Rosati, from the ICN2 Nanobioelectronics and Biosensors Group, was awarded a prize for the poster he presented, titled 'Advancements of the biosensing technologies for the preliminary biomarkers'. The other awardees were Dr David Tornai (University of Debrecen, Hungary) and Lili Meoli (King's College London, UK)

The posters to be awarded were selected by members of the MICROB-PREDICT Impact Board: project coordinator Prof. Jonel Trebicka (Münster University Hospital-UKM, Germany), ICREA Prof. Arben Merkoçi (ICN2, Spain), Marko Korenjak (president of the European Liver Patients' Association-ELPA, Belgium) and Dr Robert Schierwagen (UKM, Germany).

MICROB-PREDICT is a project involving 22 European institutions, which have joined forces to improve the prevention and treatment of chronic liver disease (cirrhosis). The project aims to identify microbiome-based biomarkers and mechanisms that predict in advance when the body can no longer compensate for the dysfunctional liver (decompensated cirrhosis) and when cirrhosis will progress to acute-on-chronic liver failure (ACLF). On the basis on such biomarkers, novel diagnostic tools for earlier and better patient stratification can be developed, which will allow personalised and effective treatment strategies.

This project has received funding from the European Union, through the Horizon 2020 Research and Innovation Programme (grant agreement No 825694).